Matching Treatment Sequences to Specific Patients

Chapter 6

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal sequencing of therapies in metastatic castration resistant prostate cancer.

Chapter 1

Targeted Treatment with Abiraterone and Enzalutamide

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Chapter 2

Targeted Treatment with Abiraterone and Enzalutamide (Cont)

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Chapter 3

Radium-223: Patient Selection and Timing of Treatment

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss radium-223 in treatment of mCRPC with bone metastases.

Chapter 4

The Role of Cabazitaxel and Docetaxel in mCRPC

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the role of cytotoxic chemotherapy in treatment of castration resistant prostate cancer and metastatic castration resistant prostate cancer.

Chapter 5

Sipuleucel-T Immunotherapy: Its Place in the mCRPC Treatment Paradigm

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss immunotherapy approaches to treatment of metastatic castration resistant prostate cancer.

Chapter 7

Trigger Points for Starting Androgen Deprivation Therapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss androgen deprivation therapy in advanced/metastatic prostate cancer.

Chapter 8

Appropriate Candidates for Intermittent ADT

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss optimal duration of androgen deprivation in the treatment of high-risk and very high-risk locally advanced prostate cancer.

Chapter 9

Docetaxel in Combination with Androgen Deprivation Therapy

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the use of docetaxel in combination with androgen deprivation therapy in men with prostate cancer.

Chapter 10

Mechanisms of ADT Resistance

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss resistance to androgen deprivation therapy in men with prostate cancer.

Chapter 11

Appropriate Candidates for ADT + Radiation

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss the use of radiation with androgen deprivation therapy in men with prostate cancer.

Chapter 12

The Future: DNA Repair Defects, Immune Checkpoint Inhibitors

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss their predictions for advances in the treatment of men with prostate cancer in next 5 years.

Speakers
Philip Kantoff, MD Philip Kantoff, MD, Director of the Lank Center for Genitourinary Oncology, Vice Chair and Chief of the Division of Solid Tumor Oncology, Department of Medical Oncology at the Dana-Farber Cancer Institute and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School in Boston, Massachusetts
Andrew J. Armstrong, MD Andrew J. Armstrong, MD, Associate Professor of Medicine and Surgery, Associate Director for Clinical Research in Genitourinary Oncology at the Duke Cancer Institute, Divisions of Medical Oncology and Urology at Duke University in Durham, North Carolina
A. Oliver Sartor, MD A. Oliver Sartor, MD, Medical Director at the Tulane Cancer Center; C.E. and Bernadine Laborde Professor of Cancer Research; and Professor in the Departments of Medicine and Urology at Tulane Medical School in New Orleans, Louisiana
William K. Oh, MD William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; Dr. Ezra M. Greenspan Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine; and Associate Director for Clinical Research at The Tisch Cancer Institute in New York, New York

Sign Up for Free e-newsletters